Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial.

Joao Pedro Ferreira Catherine M ViscoliMichaela MattheusThomas MeinickeDominik SteublChristoph WannerBernard Zinman

Published in: Diabetes, obesity & metabolism (2021)

Empagliflozin reduced UA levels and the composite of gout episodes or prescription of antigout medication. These clinically important findings expand the utility of empagliflozin as a potential antigout treatment in patients with T2D, beyond its well-established cardio-renal benefits.

Keyphrases

uric acid
metabolic syndrome
type diabetes
cardiovascular disease
study protocol
healthcare
clinical trial
emergency department
phase ii
insulin resistance
replacement therapy
electronic health record
drug induced